PeptideScanner retained ClinicalTrials.gov record NCT01128192 at 2026-11-15T22:05:38.400Z. Its registry update date was 2014-12-25, and PeptideScanner's reviewed identity mapping was pasireotide.
PeptideScanner retained ClinicalTrials.gov record NCT01382719 at 2026-07-30T21:54:46.551Z. Its registry update date was 2014-12-18, and PeptideScanner's reviewed identity mapping was bremelanotide.
PeptideScanner retained ClinicalTrials.gov record NCT01507389 at 2026-07-30T21:54:46.547Z. Its registry update date was 2014-12-09, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01435083 at 2026-11-16T01:33:21.554Z. Its registry update date was 2014-12-05, and PeptideScanner's reviewed identity mapping was desmopressin.
PeptideScanner retained ClinicalTrials.gov record NCT00317395 at 2026-11-15T21:59:29.646Z. Its registry update date was 2014-12-03, and PeptideScanner's reviewed identity mapping was eptifibatide.
PeptideScanner retained ClinicalTrials.gov record NCT02305069 at 2026-07-30T21:54:46.552Z. Its registry update date was 2014-12-02, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT00412061 at 2026-07-30T21:54:46.554Z. Its registry update date was 2014-11-21, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT00379522 at 2026-11-15T22:08:31.832Z. Its registry update date was 2014-11-05, and PeptideScanner's reviewed identity mapping was vasopressin.
PeptideScanner retained ClinicalTrials.gov record NCT01645241 at 2026-11-15T22:03:26.540Z. Its registry update date was 2014-10-27, and PeptideScanner's reviewed identity mapping was ganirelix.
PeptideScanner retained ClinicalTrials.gov record NCT01524770 at 2026-07-30T21:54:46.539Z. Its registry update date was 2014-10-22, and PeptideScanner's reviewed identity mapping was dulaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01432938 at 2026-07-30T21:54:46.558Z. Its registry update date was 2014-10-07, and PeptideScanner's reviewed identity mapping was dulaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01436201 at 2026-07-30T21:54:46.550Z. Its registry update date was 2014-10-07, and PeptideScanner's reviewed identity mapping was dulaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01166958 at 2026-07-30T21:54:46.558Z. Its registry update date was 2014-09-22, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT01270789 at 2026-07-30T21:54:46.538Z. Its registry update date was 2014-09-12, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01237197 at 2026-07-30T21:54:46.554Z. Its registry update date was 2014-09-12, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT00573144 at 2026-11-16T01:39:41.882Z. Its registry update date was 2014-09-09, and PeptideScanner's reviewed identity mapping was nesiritide.
PeptideScanner retained ClinicalTrials.gov record NCT00801242 at 2026-11-15T21:52:09.579Z. Its registry update date was 2014-09-03, and PeptideScanner's reviewed identity mapping was degarelix.
PeptideScanner retained ClinicalTrials.gov record NCT01132846 at 2026-11-16T01:39:41.882Z. Its registry update date was 2014-08-21, and PeptideScanner's reviewed identity mapping was nesiritide.
PeptideScanner retained ClinicalTrials.gov record NCT01534182 at 2026-11-16T17:42:50.457Z. Its registry update date was 2014-08-08, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
PeptideScanner retained ClinicalTrials.gov record NCT01549613 at 2026-11-15T22:01:45.056Z. Its registry update date was 2014-08-01, and PeptideScanner's reviewed identity mapping was daptomycin.
PeptideScanner retained ClinicalTrials.gov record NCT01109654 at 2026-11-15T22:02:39.332Z. Its registry update date was 2014-07-16, and PeptideScanner's reviewed identity mapping was cetrorelix.
PeptideScanner retained ClinicalTrials.gov record NCT01354405 at 2026-07-30T21:54:46.540Z. Its registry update date was 2014-07-09, and PeptideScanner's reviewed identity mapping was lanreotide.
PeptideScanner retained ClinicalTrials.gov record NCT01440881 at 2026-11-16T01:39:41.882Z. Its registry update date was 2014-06-06, and PeptideScanner's reviewed identity mapping was nesiritide.
PeptideScanner retained ClinicalTrials.gov record NCT01669291 at 2026-07-30T21:54:46.557Z. Its registry update date was 2014-06-04, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT00521300 at 2026-07-30T21:54:46.544Z. Its registry update date was 2014-06-02, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT01088529 at 2026-07-30T21:54:46.544Z. Its registry update date was 2014-05-15, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT01160328 at 2026-07-30T21:54:46.559Z. Its registry update date was 2014-05-14, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT00624195 at 2026-11-16T01:41:15.051Z. Its registry update date was 2014-04-23, and PeptideScanner's reviewed identity mapping was enfuvirtide.
PeptideScanner retained ClinicalTrials.gov record NCT00894803 at 2026-11-15T21:59:29.646Z. Its registry update date was 2014-04-17, and PeptideScanner's reviewed identity mapping was eptifibatide.
PeptideScanner retained ClinicalTrials.gov record NCT01465503 at 2026-11-15T21:58:19.888Z. Its registry update date was 2014-04-08, and PeptideScanner's reviewed identity mapping was bivalirudin.
PeptideScanner retained ClinicalTrials.gov record NCT00211887 at 2026-11-16T17:42:50.457Z. Its registry update date was 2014-04-03, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
PeptideScanner retained ClinicalTrials.gov record NCT00405639 at 2026-11-16T01:39:41.882Z. Its registry update date was 2014-03-17, and PeptideScanner's reviewed identity mapping was nesiritide.
PeptideScanner retained ClinicalTrials.gov record NCT01225835 at 2026-11-15T22:02:39.332Z. Its registry update date was 2014-03-14, and PeptideScanner's reviewed identity mapping was cetrorelix.
PeptideScanner retained ClinicalTrials.gov record NCT01611571 at 2026-07-30T21:54:46.552Z. Its registry update date was 2014-03-04, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT00813202 at 2026-11-16T01:39:41.882Z. Its registry update date was 2014-02-28, and PeptideScanner's reviewed identity mapping was nesiritide.
PeptideScanner retained ClinicalTrials.gov record NCT01550653 at 2026-07-30T21:54:46.545Z. Its registry update date was 2014-02-27, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01185704 at 2026-11-15T22:02:39.332Z. Its registry update date was 2014-02-13, and PeptideScanner's reviewed identity mapping was cetrorelix.
PeptideScanner retained ClinicalTrials.gov record NCT01216072 at 2026-11-16T17:42:50.457Z. Its registry update date was 2014-02-10, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
PeptideScanner retained ClinicalTrials.gov record NCT01093729 at 2026-11-16T17:34:46.889Z. Its registry update date was 2014-02-07, and PeptideScanner's reviewed identity mapping was efpeglenatide.
PeptideScanner retained ClinicalTrials.gov record NCT01916265 at 2026-07-30T21:54:46.545Z. Its registry update date was 2014-02-05, and PeptideScanner's reviewed identity mapping was glucagon.
PeptideScanner retained ClinicalTrials.gov record NCT01250717 at 2026-11-15T21:50:32.222Z. Its registry update date was 2014-02-04, and PeptideScanner's reviewed identity mapping was goserelin.
PeptideScanner retained ClinicalTrials.gov record NCT01339091 at 2026-11-16T17:37:42.807Z. Its registry update date was 2014-01-31, and PeptideScanner's reviewed identity mapping was dalbavancin.
PeptideScanner retained ClinicalTrials.gov record NCT00003124 at 2026-07-30T21:54:46.538Z. Its registry update date was 2014-01-06, and PeptideScanner's reviewed identity mapping was leuprolide.